Home> Products> moderate hepatic impairment

{ "products": [ { "_id": "695b65af2800555f6696a6cf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Cinacalcet 60 mg Tablet", "description": "CINASELECT 60: Comprehensive Guide to Cinacalcet 60 mg Tablets\nProduct Overview\nCINASELECT 60 is a pharmaceutical formulation containing Cinacalcet hydrochloride 60 mg as its active ingredient. This medication represents a significant advancement in the management of calcium metabolism disorders, particularly in patients with chronic kidney disease and parathyroid conditions. As a calcimimetic agent, CINASELECT 60 works by mimicking the action of calcium on tissues, helping to restore hormonal balance and mineral homeostasis in the body.\nThe 60 mg dosage strength offers an effective therapeutic option for patients requiring moderate to higher-level intervention in managing parathyroid hormone levels and associated calcium imbalances. CINASELECT 60 is manufactured under strict quality control standards, ensuring consistency, purity, and efficacy in every tablet.\nUnderstanding How CINASELECT 60 Works\nCINASELECT 60 operates through a sophisticated mechanism that targets the calcium-sensing receptors located on the surface of parathyroid gland cells. These receptors play a crucial role in regulating parathyroid hormone secretion, which in turn controls calcium and phosphorus levels in the bloodstream.\nWhen you take CINASELECT 60, the active ingredient cinacalcet binds to these calcium-sensing receptors, increasing their sensitivity to extracellular calcium. This enhanced sensitivity tricks the parathyroid glands into “thinking” there is more calcium present in the blood than there actually is. As a result, the glands reduce their production and release of parathyroid hormone (PTH).\nBy lowering PTH levels, CINASELECT 60 subsequently reduces calcium levels in the blood and decreases the amount of phosphorus absorbed from the intestines. This cascade effect helps restore the delicate mineral balance that is often disrupted in patients with kidney disease or parathyroid disorders.\nPrimary Therapeutic Uses\nSecondary Hyperparathyroidism in Chronic Kidney Disease\nThe primary indication for CINASELECT 60 is the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are on dialysis. When kidneys fail to function properly, they cannot adequately regulate calcium and phosphorus levels, leading to excessive parathyroid hormone production. This condition can result in serious complications including bone disease, cardiovascular calcification, and increased mortality risk.\nCINASELECT 60 helps manage this condition by controlling PTH levels, thereby reducing the risk of bone complications such as osteitis fibrosa cystica and preventing the dangerous deposition of calcium in blood vessels and soft tissues.\nHypercalcemia in Parathyroid Carcinoma\nCINASELECT 60 is also indicated for treating hypercalcemia (elevated blood calcium levels) in patients with parathyroid carcinoma, a rare malignant tumor of the parathyroid glands. In these cases, the medication helps control the dangerously high calcium levels that can lead to kidney stones, bone pain, digestive issues, and neurological symptoms.\nPrimary Hyperparathyroidism\nFor patients with severe hypercalcemia due to primary hyperparathyroidism who cannot undergo parathyroidectomy or for whom surgery has failed, CINASELECT 60 offers a valuable medical management option. This provides relief for patients who are not surgical candidates due to advanced age, comorbidities, or other contraindications.\nKey Benefits of CINASELECT 60\nEffective PTH Control\nClinical studies have demonstrated that CINASELECT 60 significantly reduces parathyroid hormone levels in a dose-dependent manner. This reduction helps prevent the cascade of complications associated with elevated PTH, including bone mineral loss and cardiovascular calcification.\nImproved Calcium-Phosphorus Balance\nBy reducing PTH secretion, CINASELECT 60 helps normalize serum calcium and phosphorus levels. This is particularly important in dialysis patients, where mineral imbalances can lead to serious complications affecting bone health, cardiovascular function, and overall quality of life.\nReduced Cardiovascular Risk\nElevated calcium and phosphorus levels contribute to vascular calcification, a major risk factor for cardiovascular disease in patients with chronic kidney disease. By managing these mineral levels, CINASELECT 60 may help reduce the risk of cardiovascular complications, which are the leading cause of death in dialysis patients.\nBone Health Preservation\nUncontrolled secondary hyperparathyroidism leads to renal osteodystrophy, a condition characterized by abnormal bone metabolism. CINASELECT 60 helps protect bone integrity by normalizing PTH levels, potentially reducing fracture risk and preserving bone mineral density.\nAlternative to Surgery\nFor patients with primary hyperparathyroidism or parathyroid carcinoma who cannot undergo surgery, CINASELECT 60 provides an effective medical management option. This is particularly valuable for elderly patients or those with multiple comorbidities that make surgery risky.\nQuality of Life Improvement\nBy controlling symptoms associated with hypercalcemia and hyperparathyroidism, such as bone pain, muscle weakness, fatigue, and digestive issues, CINASELECT 60 can significantly improve patients' overall quality of life and functional capacity.\nConvenient Oral Administration\nCINASELECT 60 is administered orally, making it more convenient than injectable alternatives. This allows for outpatient management and reduces the burden on healthcare facilities and patients.\nPotential Side Effects and Adverse Reactions\nCommon Side Effects\nPatients taking CINASELECT 60 may experience several common side effects, which typically include nausea and vomiting, occurring in approximately 20-30% of patients. These gastrointestinal symptoms are usually mild to moderate and may improve over time as the body adjusts to the medication.\nDiarrhea is another frequent complaint, affecting roughly 20% of users. Some patients also report muscle pain or myalgia, dizziness, loss of appetite, and asthenia (general weakness or fatigue).\nSerious Side Effects Requiring Medical Attention\nHypocalcemia: The most significant risk associated with CINASELECT 60 is the development of low calcium levels in the blood. Severe hypocalcemia can lead to paresthesias (tingling sensations), muscle cramps or spasms, tetany, seizures, and QT interval prolongation on electrocardiogram, which can predispose to dangerous heart rhythm abnormalities.\nGastrointestinal Bleeding: There have been reports of gastrointestinal hemorrhage in patients taking cinacalcet, particularly in those with risk factors such as gastritis, ulcers, or concurrent use of other medications that increase bleeding risk.\nAdynamic Bone Disease: Oversuppression of PTH can lead to adynamic bone disease, a condition where bone turnover becomes abnormally low, potentially weakening bones despite normalized calcium levels.\nCardiovascular Effects: Some patients may experience worsening heart failure or arrhythmias, particularly if hypocalcemia develops. Close monitoring is essential in patients with underlying cardiovascular disease.\nAllergic Reactions: Though rare, hypersensitivity reactions including rash, urticaria, and angioedema have been reported.\nPrecautions and Contraindications\nCINASELECT 60 should not be used in patients with serum calcium levels below the normal range. It requires careful dose adjustment and monitoring in patients with hepatic impairment. The medication may interact with drugs metabolized by the CYP2D6 enzyme system and with medications that affect gastric pH.\nPregnant or breastfeeding women should use CINASELECT 60 only if clearly needed, as its safety in these populations has not been fully established. Regular monitoring of serum calcium, phosphorus, and PTH levels is essential throughout treatment.\nDosage and Administration Guidelines\nCINASELECT 60 should be taken orally with food or shortly after a meal, as this improves absorption and reduces gastrointestinal side effects. Tablets should be swallowed whole and not crushed, chewed, or divided.\nThe typical starting dose for secondary hyperparathyroidism is lower than 60 mg, with gradual titration based on PTH and calcium levels. The 60 mg strength is often used as part of the dose escalation process or as a maintenance dose once optimal PTH control is achieved.\nDose adjustments should be made no more frequently than every two to four weeks, as it takes this long to see the full effect of a dose change on PTH levels. Treatment should be individualized based on laboratory values and clinical response.\nMonitoring Requirements\nPatients on CINASELECT 60 require regular monitoring of serum calcium, phosphorus, and intact PTH levels. Calcium levels should be checked within one week of starting treatment or after any dose adjustment, and then monthly once stable. PTH levels should be measured one to four weeks after initiation or dose adjustment, then every one to three months during maintenance therapy.\nAdditionally, patients should be monitored for signs and symptoms of hypocalcemia, particularly during the initial treatment period. Electrocardiogram monitoring may be appropriate in patients at risk for QT prolongation.\nStorage and Handling\nCINASELECT 60 should be stored at room temperature, away from moisture and direct sunlight. The medication should be kept in its original container with the lid tightly closed to protect from humidity. Keep out of reach of children and pets. Do not use past the expiration date printed on the package.\nConclusion\nCINASELECT 60 (Cinacalcet 60 mg) represents a valuable therapeutic option in the management of secondary hyperparathyroidism associated with chronic kidney disease, hypercalcemia in parathyroid carcinoma, and primary hyperparathyroidism in patients who cannot undergo surgery. Its unique mechanism as a calcimimetic agent provides effective control of parathyroid hormone secretion, helping to restore mineral balance and prevent serious complications.\nThe benefits of CINASELECT 60 extend beyond simple laboratory value normalization. By controlling PTH, calcium, and phosphorus levels, this medication helps preserve bone health, reduce cardiovascular calcification risk, and improve overall quality of life for patients dealing with complex metabolic disorders. For patients who are not surgical candidates, CINASELECT 60 offers hope and effective symptom management.\nHowever, like all medications, CINASELECT 60 must be used judiciously under close medical supervision. The risk of hypocalcemia and other potential side effects necessitates regular laboratory monitoring and open communication between patients and healthcare providers. Patients should report any concerning symptoms promptly and attend all scheduled follow-up appointments.", "price": 740.0, "discountamount": 222.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2266, "imageuri": "https://productimages.withfloats.com/actual/695b65ebf30763183f64d4f7.png", "tileimageuri": "https://productimages.withfloats.com/tile/695b65ebf30763183f64d4f7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-01-05T07:18:07.264Z", "updatedon": "2026-05-01T06:30:26.075Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/cinacalcet-60-mg-tablet/2266", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CINASELECT 60", "category": "NEPHROLOGYRANGE", "tags": [ "cinacalcet 60 mg", "cinacalcet mechanism of action.", "cinacalcet uses", "tab cinacalcet.", "cinacalcet dose.", "cinacalcet structure.", "cinacalcet tab.", "calcium and phosphorus levels in the bloodstream.", "parathyroid hormone secretion.", "calcium metabolism disorders.", "chronic kidney disease and parathyroid conditions.", "cinacalcet 60 mg", "cinacalcet 60", "Cinacalcet Tablets 60 mg price in India", "Buy Cinacalcet Tablets 60 mg online", "Cinacalcet 60 mg wholesale price", "Buy Cinacalcet Tablets 60 mg", "Get Cinacalcet Tablets 60 mg at best price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694919f0de5d3e57a93413a8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "elagolix 150mg tablet", "description": "Eligolux 150 delivers 150mg of elagolix per tablet, formulated as an oral, once-daily option in convenient packs for ongoing therapy. As a non-peptide GnRH receptor antagonist, it selectively suppresses pituitary gonadotropins, reducing ovarian estrogen production without the flare effect of agonists. Ideal for patients with milder symptoms or those prioritizing bone health, this dose minimizes hypoestrogenic risks while targeting endometriotic pain.\n\nTake Eligolux 150 whole with water, with or without food, preferably at the same time daily. Storage requires a cool, dry environment below 30°C, away from children and moisture. Steris Healthcare ensures GMP-compliant manufacturing, making it accessible across India for endometriosis care.\n\nPrimary Uses and Indications\nEligolux 150 primarily treats moderate endometriosis-associated pain, including dysmenorrhea, chronic pelvic discomfort, and dyspareunia. Endometriosis impacts 10% of reproductive-age women, causing ectopic endometrial growth that triggers inflammation and scarring; elagolix 150mg curbs estrogen-driven progression.\n​\nPrescribed when NSAIDs or combined pills prove inadequate, it excels in non-severe cases, allowing prolonged use. Emerging evidence supports its role in heavy menstrual bleeding from fibroids, though primary approval focuses on pain relief. Start therapy within the first week of menses for optimal synchronization.\n​\nMechanism of Action\nElagolix in Eligolux 150 competitively binds GnRH receptors, dose-dependently inhibiting LH/FSH release. This lowers estradiol by 40-60%—less aggressive than 200mg—halting endometrial tissue proliferation outside the uterus. Peak levels hit in 1 hour, with a 4-6 hour half-life supporting steady-state suppression on QD dosing.\n​\nUnlike agonists, no initial hormone surge occurs, preventing worsened pain. Partial estrogen reduction preserves some bone-protective effects, differentiating it from deeper suppression therapies.\n\nKey Benefits\nEligolux 150 shines in clinical responsiveness: phase 3 trials showed 32% dysmenorrhea resolution versus 20% placebo at 6 months, with 50% pain score drops. Quality-of-life gains include better work attendance, sleep, and relationships, per EQ-5D assessments.\n​\nExtended 24-month approval suits long-term control, with amenorrhea in 40-50% of users reducing bleeding volume by 70%. Oral ease beats injectables, enhancing adherence at 85% in studies. Lower BMD impact (0.5-1% loss/year) allows safer continuation versus higher doses.\n\nBenefit\tTrial Data\tPatient Impact\nPain Reduction\t32-50% dysmenorrhea-free \n​\tDaily activity restoration\nBleeding Control\t70% volume drop \n​\tAnemia prevention\nLong-Term Use:\tUp to 24 months \n​\tSustained relief\nQoL Improvement\tEQ-5D gains \n​\tEmotional well-being\nPotential Side Effects\nVasomotor symptoms dominate: hot flashes (20-30%), headaches (17%), and night sweats (10-15%) emerge early but fade. Nausea (8%), insomnia (7%), and mild depression (5%) affect minorities, with a 70% event rate mostly grade 1.\n​\nBMD decline averages -0.9% at the spine after 12 months, monitored via DEXA. Discontinuation hovers at 5-8%.\n\nSide Effect\tIncidence\tMitigation\nHot Flashes\t20-30% \n​\tVentilation, timing\nHeadache\t17% \n​\tAnalgesics\nBMD Loss\t0.9% \n​\tSupplements, scans\nMood Shifts\t5% \n​\tMonitoring\nSerious Risks and Management\nSuicidality (0.1-0.5%) demands baseline psych screening; halt if worsening. Liver enzymes rise in 1%, requiring LFTs at 3/6 months. Rare anaphylaxis or thromboembolism prompts immediate cessation. Avoid in osteoporosis or smokers >35.\n​\n\nDosage Guidelines\n150 mg once daily for up to 24 months in normal/mild liver function; limit to 6 months in moderate impairment (Child-Pugh B). No titration needed; miss a dose? Resume the next day, no doubling. Pair with 1 g calcium/800 IU vitamin D daily.\n​\n\nPrecautions and Contraindications\nPregnancy category X: mandates non-hormonal birth control during and 1 week post-therapy. Screen hepatic/renal function; avoid severe cases. CYP3A interactions (e.g., rifampin reduces efficacy) need dose review. Breastfeeding is contraindicated.\n​\nClinical Evidence and Efficacy\nElaris trials (n=1,689) confirmed superiority: co-primary endpoints met with 75% responder rates for pain. 12-month extensions showed persistent efficacy and low rebound. Versus 200mg, 150mg balances tolerability for moderate pain.\n​\nConclusion\nEligolux 150 empowers women with moderate endometriosis pain through precise, extended hormonal modulation and proven outcomes. Regular physician oversight maximizes safety and efficacy.\n", "price": 700.0, "discountamount": 210.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2252, "imageuri": "https://productimages.withfloats.com/actual/694a2af01e4092f757d90bb5.png", "tileimageuri": "https://productimages.withfloats.com/tile/694a2af01e4092f757d90bb5.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T10:14:08.773Z", "updatedon": "2026-03-26T05:59:45.544Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//elagolix-150mg-tablet/2252", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ELIGOLUX 150", "category": "GYANECOLOGYRANGE", "tags": [ "elagolix 150mg tablet", "prioritizing bone health.", "endometriotic pain.", "endometrial tissue proliferation outside the uterus.", "Eligolux 150 empowers women with moderate endometriosis pain through precise.", "hormonal modulation and proven outcomes.", "gonadotropins.", "endometriotic pain." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6948f4ee5837f90c86a7e578", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Elagolix 200mg ", "description": "Eligolux200 contains 200 mg of elagolix per tablet and is manufactured by Steris Healthcare Pvt Ltd in India as a prescription medication in packs of 3x10 tablets. Elagolix acts as a potent gonadotropin-releasing hormone (GnRH) receptor antagonist, binding competitively to GnRH receptors in the pituitary gland to rapidly reduce estrogen and progesterone levels without the initial flare-\nup seen in agonists. This mechanism starves endometrial-like tissue outside the uterus of hormonal stimulation, shrinking lesions and easing inflammation.\n\nAdminister Eligolux200 orally, swallowed whole with water, with or without food, typically starting within 7 days of menstrual onset. Standard dosing for severe cases involves 200mg twice daily for up to 6 months, or 150mg once daily extended to 24 months, adjusted by physicians based on tolerance and response. Store in a cool, dry place away from moisture and light, keeping out of children's reach.\n\nPrimary Uses\nEligolux200 targets moderate to severe endometriosis-associated pain, including dysmenorrhea (painful periods), nonmenstrual pelvic pain, and dyspareunia (painful intercourse). Endometriosis affects millions globally, causing tissue similar to the uterine lining to grow ectopically, leading to chronic inflammation, adhesions, and scarring. By dosing flexibly, Eligolux200 suits patients needing stronger suppression for intense symptoms, reducing reliance on opioids or surgery.\n\nClinical trials like Elaris EM-I and EM-II showed 75% dysmenorrhea reduction and 50-60% nonmenstrual pain relief at 6-12 months. It also curbs heavy menstrual bleeding in uterine fibroids, offering dual benefits for overlapping conditions. Physicians prescribe it when first-line NSAIDs or oral contraceptives fail, prioritizing non-invasive symptom control.\n​\n\nKey Benefits\nEligolix in Eligolux200 delivers rapid pain relief, with significant improvements in daily pain scales within 3 months versus placebo. Women report 47% better composite pelvic pain scores, enhancing daily activities, work productivity, and intimacy. Quality-of-life metrics improve consistently over 24 weeks, including reduced fatigue and better emotional well-being.\n​\n\nUnlike injectables, its oral form and dose-dependent estrogen suppression allow titration—lower doses minimize hypoestrogenic effects while higher 200mg dosing tackles severe pain. Studies confirm amenorrhea in 25% of users early on, slashing bleeding days by up to 50%. Long-term data up to 12 months with add-back therapy sustains efficacy, preserving bone health better than monotherapy. Patients regain control, avoiding invasive laparoscopies and reclaiming normalcy.\n​\n\nBenefit\tEvidence from Trials'\tImpact on Patients\nDysmenorrhea Reduction:\t75% at 6 months \n​\tFewer missed workdays\nNonmenstrual Pain Relief:\t50-60% improvement \n​\tEnhanced mobility\nBleeding Control:\t14% bleeding days vs. 24% baseline \n​\tImproved hygiene, anemia prevention\nQuality of Life\tSustained over 24 weeks \n​\tBetter sleep, relationships\nPotential Side Effects\nCommon side effects of Eligolux200 mirror hypoestrogenic states: hot flashes, night sweats, headache, and nausea, each affecting about 10% of users. These often lessen as the body adjusts, with 69.5% overall adverse event rate over 24 weeks, mostly mild. Mood changes like irritability or depression occur less commonly, warranting mood monitoring.\n​\n\nBone mineral density (BMD) loss poses a key concern—200mg twice daily causes -1.5% to -2.4% drops at lumbar spine and hip after 6 months, attenuated with calcium/vitamin D or add-back therapy. Rare serious risks include suicidal thoughts, liver enzyme elevations, or allergic reactions like anaphylaxis. Discontinuation due to events stays low at 4-12%. No deaths are linked directly to treatment in trials.\n​\n\nSide Effect Category\tFrequency\tManagement\nVasomotor (Hot Flashes)\t9.9-10% \n​\tLifestyle cooling, dose adjustment\nNeurologic (Headache)\t9.9% \n​\tHydration, analgesics\nBone Loss\tUp to 2.4% at 6 months \n​\tDEXA scans, supplements\nMood Changes\tLess common \n​\tPsychiatric screening\nPrecautions and Contraindications\nAvoid Eligolux200 in pregnancy (risk of early loss), known osteoporosis, severe hepatic impairment, or with strong OATP1B1 inhibitors like cyclosporine or gemfibrozil. Women of childbearing age need effective non-hormonal contraception during and 28 days post-therapy, as it impairs recognition of pregnancy via amenorrhea. Not for pediatrics under 18 or geriatrics lacking data.\n\nScreen for depression history, liver function, and BMD before starting; monitor quarterly. Drug interactions abound with rifampin (reduces levels) or over 50 others like clarithromycin—inform physicians fully. Breastfeeding lacks safety data; weigh risks. Regular blood/urine tests track efficacy and safety.\n​\n\nDosage Guidelines\nInitiate Eligolux200 at 150mg daily for milder cases, escalating to 200mg BID for dyspareunia or severe pain, max 6 months at higher dose. Miss a dose? Take promptly unless near the next; never double. Duration caps at 24 months total, with liver-adjusted lower dosing. Pair with add-back for extended use to curb BMD loss.\n​\n\nPhysicians tailor based on response: 74-77% complete 6-month trials. Swallow intact; no crushing.\n​\n\nClinical Evidence\nPhase III trials (Elaris EM-I/II) randomized 1689 women, proving both doses superior to placebo for co-primary endpoints of dysmenorrhea and nonmenstrual pain. Open-label extensions to 24 weeks maintained gains. A 12-month study with add-back showed persistent relief and <1% additional BMD loss versus placebo. Real-world use echoes this, positioning Eligolix as first oral GnRH antagonist approved for endometriosis.\n​\n\nVersus relugolix, Eligolix offers comparable pelvic pain reduction with adjustable dosing. Indian brands like Eligolux200 align with global standards.\n​\n\nConclusion\nEligolux200 transforms endometriosis management, delivering substantial pain relief and functional gains through precise hormonal control. Balancing robust benefits against manageable risks like BMD monitoring empowers women toward symptom-free lives. Consult healthcare providers for personalized integration into care plans.\n", "price": 1000.0, "discountamount": 300.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2251, "imageuri": "https://productimages.withfloats.com/actual/694a2b9f403179ac7e958ef6.png", "tileimageuri": "https://productimages.withfloats.com/tile/694a2b9f403179ac7e958ef6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T07:36:14.316Z", "updatedon": "2026-03-26T06:00:31.59Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//elagolix-200mg-/2251", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ELIGOLUX 200", "category": "GYANECOLOGYRANGE", "tags": [ "Elagolix Tablets 200mg", "Elagolix acts as a potent gonadotropin-releasing hormone.", "nonmenstrual pelvic pain.", "adhesions, and scarring", "preserving bone health better than monotherapy.", "avoiding invasive laparoscopies and reclaiming normalcy.", "pituitary gland to rapidly reduce estrogen and progesterone.", "tab elagolix 200mg", "elagolix 200mg.", "elagolix.", "elagolix 200.", "elagolix tablets", "elagolix tablets uses.", "elagolix 200 mg price.", "elagolix mechanism of action.", "elagolix 200 mg uses.", "tab elagolixtab elagolix." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6943af86161ad9de85f42b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "imatinib 400mg", "description": "IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​\n\nProduct Overview\nIMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​\n\nThe medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​\n\nPrimary Uses\nIMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​\n\nIn gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​\n\nHealthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​\n\nKey Benefits\nOne standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​\n\nTumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​\n\nAdditional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​\n\nPotential Side Effects\nWhile generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​\n\nMusculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​\n\nAvoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​\n\nDosage and Administration Guidelines\nSwallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​\n\nRenal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​\n\nPrecautions and Interactions\nPatients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​\n\nRegular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​\n\nConclusion\nIMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.", "price": 1827.0, "discountamount": 540.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2249, "imageuri": "https://productimages.withfloats.com/actual/6943b026ca1b0dcfc6c37820.png", "tileimageuri": "https://productimages.withfloats.com/tile/6943b026ca1b0dcfc6c37820.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-18T07:38:46.766Z", "updatedon": "2026-04-15T10:27:12.329Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//imatinib-400mg/2249", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IMATIFLOW 400", "category": "NEPHROLOGYRANGE", "tags": [ "Imatinib IP 400mg", "offering robust control over CML.", "related cancers with a balance of efficacy and manageability.", "innovative treatment maximizes hope and health in the fight against cancer.", "cancer therapy.", "fuel cancer cell growth.", "chemotherapy.", "imatinib 400mg.", "imatinib 400mg tablet.", "tab. imatinib 400mg.", "imatinib 400mg price.", "imatinib 400mg tab", "imatinib 400mg side effects.", "imatinib 400 mg tablet", "imatinib 400 mg medicine", "imatinib tablets 400 mg uses", "imatinib 400 mg dosage", "imatinib 400 mg price in india", "imatinib 400 mg brand name" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "69143c14e91a8f3f57dea824", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Rifaximin oral suspension 100mg/5ml", "description": "Rifaximin Oral Suspension 100 mg/5 ml is a broad-spectrum, gut-selective antibiotic formulated to treat various bacterial infections of the gastrointestinal tract, including traveler’s diarrhea, hepatic encephalopathy-related symptoms, and irritable bowel syndrome with diarrhea (IBS-D). Its unique non-systemic activity ensures that the drug acts locally in the intestines without significant absorption into the bloodstream, making it both effective and safe for long-term gastrointestinal management.\n\nDesigned in a pleasant-tasting, easy-to-administer oral suspension form, Rifaximin 100 mg/5 ml is especially suitable for pediatric patients and adults who have difficulty swallowing tablets. It is ideal for treating infections caused by non-invasive strains of Escherichia coli and other enteric bacteria, while also helping maintain intestinal balance and promoting recovery from gut-related complications.\nComposition\nEach 5 ml of suspension contains:\n\nRifaximin IP – 100 mg\n\nFlavored base and excipients – q.s.\n\nDosage Form: Oral Suspension\nAppearance: Pink to reddish suspension (depending on brand formulation)\nPackaging: Available in 30 ml, 60 ml, or 100 ml bottles with a measuring cup for accurate dosing.\n\nPharmacological Action and Mechanism\nRifaximin belongs to the rifamycin class of antibiotics and is structurally related to rifampicin. However, it has been specially modified to act locally in the gastrointestinal tract with negligible systemic absorption (<0.4%).\nMechanism of Action:\nRifaximin inhibits bacterial RNA synthesis by binding to the β-subunit of the bacterial DNA-dependent RNA polymerase.\nThis action prevents the transcription process, thereby stopping bacterial growth and replication.\nIts broad-spectrum activity covers both gram-positive and gram-negative bacteria, including aerobic and anaerobic strains.\nDue to poor absorption, it remains in the intestine at high concentrations, providing localized antibacterial effect without systemic toxicity.\n\nAdditionally, Rifaximin exerts eubiotic effects — it helps restore normal intestinal flora balance by selectively targeting harmful bacteria, which makes it useful for chronic intestinal disorders.\nUses and Indications\nRifaximin Oral Suspension 100 mg/5 ml is indicated for the following conditions:\n\nTraveler’s Diarrhea (TD):\n\nCaused by non-invasive strains of Escherichia coli.\nHelps relieve symptoms like watery stools, abdominal cramps, and bloating within a short duration.\nHepatic Encephalopathy (HE):\n\nUsed as adjunct therapy to reduce ammonia-producing gut bacteria, thereby lowering blood ammonia levels and improving mental status in patients with chronic liver disease.\n\nIrritable Bowel Syndrome with Diarrhea (IBS-D):\nProvides relief from abdominal pain, bloating, and irregular bowel movements by reducing bacterial overgrowth in the small intestine (SIBO).\nSmall Intestinal Bacterial Overgrowth (SIBO):\nHelps normalize gut flora and reduces gas, bloating, and discomfort caused by bacterial overgrowth.\nGastrointestinal Infections in Children:\nEffective in pediatric patients suffering from infectious diarrhea due to bacterial contamination of food or water.\n\nProphylactic Use:\nMay be prescribed post-surgery or in chronic liver disease to prevent recurrence of infection-related complications.\nDosage and Administration\nAdults and Children (>12 years): Usual dose is 10–20 ml (200–400 mg) every 8–12 hours, depending on the indication and physician’s recommendation.\nChildren (2–12 years): 5–10 ml (100–200 mg) two or three times daily, as directed by a pediatrician.\nShake the bottle well before each use.\nComplete the prescribed course even if symptoms improve early to prevent recurrence and antibiotic resistance.\nKey Benefits\nGut-Selective Action:\nActs locally within the intestine without entering systemic circulation, ensuring targeted therapy with minimal side effects.\n\nBroad-Spectrum Antibacterial Activity:\nEffective against a wide range of gram-positive, gram-negative, aerobic, and anaerobic enteric pathogens.\nSafe for Pediatric and Adult Use:\nThe liquid form allows accurate dosing and ease of administration, especially for children or elderly patients.\n\nMinimal Systemic Absorption:\nReduces the risk of systemic toxicity and drug interactions compared to conventional antibiotics.\nEffective for Traveler’s Diarrhea:\nRapidly controls diarrhea symptoms caused by E. coli and restores normal intestinal function.\nImproves Liver Health in Hepatic Encephalopathy:\nDecreases ammonia-producing bacteria, thereby reducing confusion, lethargy, and other symptoms related to hepatic encephalopathy.\n\nRestores Gut Microbiota Balance:\nHelps maintain healthy intestinal flora, supporting digestion and preventing recurrent infections.\n\nReduces Bloating and Abdominal Discomfort in IBS-D:\nProvides symptomatic relief and enhances quality of life in patients suffering from chronic bowel irregularities.\nLow Risk of Resistance:\nDue to its minimal absorption and targeted mechanism, the development of bacterial resistance is significantly lower.\nWell-Tolerated Formulation:\nThe oral suspension is gentle on the stomach and has a pleasant taste, improving compliance in children and adults alike.\n\nPrecautions and Warnings\n\nWhile Rifaximin Oral Suspension is considered safe for most patients, the following precautions should be observed:\n\nAllergy: Avoid use in patients with known hypersensitivity to rifaximin, rifampicin, or other rifamycin derivatives.\n\nSevere Diarrhea or Bloody Stool: If symptoms worsen or persist beyond 48 hours, consult a physician; may indicate an invasive infection requiring alternative therapy.\n\nLiver Impairment: Use with caution in patients with severe hepatic impairment; dosage adjustments may be required.\n\nPregnancy and Lactation: Limited data available; should be used only if clearly needed and prescribed by a doctor.\n\nLong-Term Use: Prolonged or unnecessary use may lead to superinfection by non-susceptible organisms, including fungi.\n\nDriving and Machinery: Generally safe, but dizziness or fatigue may occur in rare cases.\n\nPossible Side Effects\n\nRifaximin is generally well-tolerated due to its localized action in the gut. However, some mild to moderate side effects may occur in sensitive individuals.\n\nCommon Side Effects:\n\nNausea\n\nFlatulence (gas)\n\nAbdominal pain or cramping\n\nHeadache\n\nBloating\n\nConstipation\n\nLess Common / Rare Side Effects:\n\nSkin rash or itching\n\nDizziness or fatigue\n\nElevated liver enzymes (rare)\n\nVomiting or dry mouth\n\nFever or flu-like symptoms\n\nSerious Side Effects (Very Rare):\n\nAllergic reaction (rash, swelling, or breathing difficulty)\n\nPersistent watery or bloody diarrhea\n\nSevere abdominal pain\n\nIf any severe adverse reactions occur, discontinue use and seek medical attention immediately.\n\nStorage and Handling\n\nStore below 30°C in a cool, dry place.\n\nProtect from direct sunlight and freezing.\n\nShake well before use.\n\nKeep out of reach of children.\n\nDiscard any unused portion after the treatment course or expiry date.\n\nConclusion\n\nRifaximin Oral Suspension 100 mg/5 ml is a clinically trusted and patient-friendly antibiotic formulation for the treatment of gastrointestinal infections and liver-related complications. Its unique non-systemic mode of action, combined with broad antibacterial efficacy, makes it an excellent choice for both acute and chronic intestinal disorders.\n\nUnlike traditional antibiotics that circulate systemically, Rifaximin works locally within the intestines to eliminate harmful bacteria while preserving the natural gut flora. This results in faster relief from symptoms like diarrhea, bloating, and abdominal discomfort — with minimal side effects.\nWhether used for traveler’s diarrhea, hepatic encephalopathy, IBS-D, or bacterial overgrowth syndromes, Rifaximin offers targeted, safe, and effective therapy for restoring digestive health and improving overall well-being.", "price": 170.0, "discountamount": 51.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2204, "imageuri": "https://productimages.withfloats.com/actual/69143c160712d1e28ab8336e.png", "tileimageuri": "https://productimages.withfloats.com/tile/69143c160712d1e28ab8336e.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-11-12T07:49:40.243Z", "updatedon": "2026-03-12T07:37:08.06Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//rifaximin-oral-suspension-100mg-5ml/2204", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RIFAXEMANIA KID", "category": "Pediatric", "tags": [ "Rifaximin Oral Suspension 100 mg/5 ml", "antibiotic", "astrointestinal management.", "Rifaximin IP – 100 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "685d3aee734cdee72771a953", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "rifaximin 200", "description": "RIFAXEMANIA 200 is a targeted intestinal antibiotic that contains Rifaximin 200 mg. This medication is widely used to treat gastrointestinal infections without affecting the rest of the body. Because of its poor absorption into the bloodstream, it works directly in the digestive tract, helping to treat infections like traveler’s diarrhea, IBS-D (Irritable Bowel Syndrome with Diarrhea), and complications related to liver conditions such as hepatic encephalopathy. RIFAXEMANIA 200 is formulated in tablet form, offering convenience, precision, and effective relief.\n\nWhat is Rifaximin 200 mg?\nRifaximin 200 mg is a non-systemic, semi-synthetic antibiotic derived from the rifamycin group. It functions by binding to bacterial RNA polymerase, preventing bacteria from multiplying. Since it stays confined to the gastrointestinal tract and is not absorbed significantly into the bloodstream, it’s ideal for treating localized gut infections.\n\nThis unique property makes the rifaximin 200 tablet suitable for conditions that do not require full-body antibiotic exposure, ensuring effective treatment with minimal side effects.\n\nUses of Rifaximin 200 Tablet\nRifaximin 200 mg is prescribed in tablet form to treat a variety of gut-related conditions. Common uses include the treatment of traveler’s diarrhea caused by non-invasive strains of E. coli, reducing the recurrence of hepatic encephalopathy in individuals with chronic liver disease, and relieving symptoms associated with IBS-D such as diarrhea, bloating, and abdominal pain.\n\nAdditionally, rifaximin is sometimes used to manage small intestinal bacterial overgrowth (SIBO), functional digestive disorders, and as part of combination therapy in certain inflammatory bowel conditions. These rifaximin 200 mg uses make it a valuable option for both acute and chronic digestive health management.\n\nSide Effects of Rifaximin 200 mg\nRifaximin is generally considered safe and well-tolerated due to its low systemic absorption. However, like all medications, some individuals may experience side effects. These can include nausea, abdominal pain, bloating, headache, constipation, or mild diarrhea. In rare cases, allergic skin reactions or fatigue may occur.\n\nMost of these effects are mild and temporary. If symptoms persist or worsen, it is advisable to contact a healthcare professional for further evaluation.\n\nPrecautions Before Using RIFAXEMANIA 200\nBefore using RIFAXEMANIA 200, patients should consider a few important precautions. Anyone with a known allergy to rifaximin or related antibiotics in the rifamycin class should avoid this medication. It should also be used cautiously in people with moderate to severe liver disease, as systemic absorption may be higher in such cases.\n\nPregnant or breastfeeding individuals should only use this product after consulting a physician. Rifaximin 200 mg is not recommended in cases of bloody diarrhea or fever, where a more systemic antibiotic may be required. Proper diagnosis and physician supervision are essential before starting treatment.\n\nDrug Interactions with Rifaximin 200 mg\nAlthough rifaximin is minimally absorbed into the bloodstream, it may still interact with certain medications, particularly in patients with liver impairment. For example, cyclosporine can significantly raise blood levels of rifaximin, requiring dose adjustments.\n\nOther drugs that may interact include warfarin (where INR monitoring is necessary), oral contraceptives (as effectiveness may decrease), and antiepileptic medications (which may have altered therapeutic effects). Always inform your doctor about all current medications, including over-the-counter supplements and herbal products, before starting rifaximin 200 tablet.\n\nWhy RIFAXEMANIA 200 is Recommended\nRIFAXEMANIA 200 offers precise and localized antibacterial action in the intestines without exposing the rest of the body to unnecessary drug effects. This makes it a preferred option for managing conditions like traveler’s diarrhea, hepatic encephalopathy, and IBS-D. Its convenient tablet form, reliable safety profile, and effectiveness in reducing symptoms make it a valuable part of modern gastrointestinal therapy.\n\nConclusion\nRIFAXEMANIA 200, containing Rifaximin 200 mg, is a clinically effective and safe treatment for bacterial infections limited to the gastrointestinal tract. With minimal absorption and a strong local antibacterial effect, it helps address common and chronic digestive conditions while minimizing adverse effects. Whether you are managing liver-related complications or looking for relief from persistent diarrhea and gut discomfort, RIFAXEMANIA 200 delivers dependable results.\n\nAlways follow your healthcare provider’s instructions for dosage and duration to ensure the best possible outcomes.\n\n", "price": 149.0, "discountamount": 45.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "rifaxemania 200", "rifaxemania 200 patients", "breastfeeding individuals", "valuable part", "current medications", "antiepileptic medications", "cases pregnant", "mild diarrhea", "effective relief", "rifaxemania 200rifaxemania 200", "rifaximin 200 mg", "persistent diarrhea", "safe treatment", "clinically effective", "preferred option", "herbal products", "overthecounter supplements", "oral contraceptives", "inr monitoring", "minimally absorbed", "physician supervision", "bloody diarrhea", "rifamycin class", "related antibiotics", "important precautions", "evaluation precautions", "welltolerated due", "valuable option", "combination therapy", "diarrhea bloating", "hepatic encephalopathy", "noninvasive strains", "tablet form", "absorbed significantly", "stays confined", "rifamycin group", "works directly", "poor absorption", "symptoms persist", "relieving symptoms", "liver impairment", "healthcare professional", "coli reducing", "complications related", "systemic absorption", "treat infections", "gastrointestinal tract", "minimal absorption", "managing conditions", "systemic antibiotic", "liver conditions", "reducing symptoms make", "treat gastrointestinal infections", "low systemic absorption", "managing liverrelated complications", "travelers diarrhea caused", "unique property makes", "minimal side effects", "chronic digestive conditions", "inflammatory bowel conditions", "gutrelated conditions common", "digestive tract helping", "healthcare providers instructions", "severe liver disease", "generally considered safe", "chronic liver disease", "targeted intestinal antibiotic", "minimizing adverse effects", "bacterial infections limited", "unnecessary drug effects", "altered therapeutic effects", "experience side effects", "helps address common", "localized antibacterial action", "required proper diagnosis" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2138, "imageuri": "https://productimages.withfloats.com/actual/685d3af25609b7ccc73e989b.png", "tileimageuri": "https://productimages.withfloats.com/tile/685d3af25609b7ccc73e989b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-26T12:19:58.961Z", "updatedon": "2026-03-12T11:08:27.109Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//rifaximin-200/2138", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RIFAXEMANIA 200", "category": "GASTROLOGYRANGE", "tags": [ "rifaximin 200", "rifaximin 200 mg uses in hindi", "rifaximin 200 mg uses", "rifaximin 200 mg tablet", "rifaximin 200 uses", "rifaximin 200 price in india", "rifaximin 200 mg tablet price", "rifaximin 200 side effects", "rifaximin 200 tablet how to use", "rifaximin 200 mg tablet for chronic diarrhea", "rifaximin 200 mg tablet for stomach infection" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "66d999cc236afd258ed10348", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Nintedanib 100 mg", "description": "NINTEDONE 100 \nNintedanib 100 mg is a cutting-edge oral medication designed to combat progressive lung conditions and certain cancers, offering hope to patients facing debilitating fibrotic diseases. As a small-molecule tyrosine kinase inhibitor, it targets key pathways involved in abnormal cell growth and tissue scarring, making it a vital therapy for idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrosing interstitial lung diseases (PF-ILD). Manufactured to high standards, this formulation delivers precise dosing in a convenient capsule form, ensuring consistent absorption and efficacy for long-term management.​\n\nUses of Nintedanib 100 mg\nNintedanib 100 mg stands out for its approved indications in slowing the decline of lung function in adults with IPF, a chronic and fatal lung disease characterized by progressive scarring of lung tissue. It is also indicated for SSc-ILD, where it helps manage lung fibrosis associated with systemic sclerosis, and PF-ILD, covering other chronic fibrosing lung conditions with a progressive phenotype. Beyond pulmonary fibrosis, Nintedanib has shown utility in oncology, particularly when combined with docetaxel for second-line treatment of advanced non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology, inhibiting tumor angiogenesis and growth.​\n\nThis medication addresses the underlying fibrotic processes by restricting fibroblast proliferation and migration, which are central to lung tissue damage. In clinical practice, physicians prescribe Nintedanib 100 mg for patients with confirmed diagnoses via high-resolution CT scans or lung biopsies, often after other treatments fail. Its versatility extends to off-label considerations in other cancers like pancreatic or colorectal, though primary use remains in respiratory fibrosis and lung cancer, providing a targeted approach where traditional therapies fall short.​\n\nKey Benefits of Nintedanib 100 mg\nOne of the primary benefits of Nintedanib 100 mg is its proven ability to reduce the rate of forced vital capacity (FVC) decline, a key measure of lung function, by up to 50% in IPF patients compared to placebo in landmark trials. This translates to slower disease progression, fewer acute exacerbations, and improved quality of life, allowing patients to maintain daily activities longer. The oral administration enhances patient compliance, avoiding the need for infusions or hospital visits.​\n\nSlows Fibrosis Progression: By inhibiting multiple tyrosine kinases, it curbs excessive scar tissue formation in the lungs, preserving respiratory capacity over time.​\n\nAnti-Angiogenic Effects: In cancer settings, it blocks vascular endothelial growth factor receptors (VEGFR), reducing tumor blood supply and metastasis risk.​\n\nBroad-Spectrum Kinase Inhibition: Targets fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and others, addressing multifaceted disease pathways.​\n\nManageable Long-Term Use: Clinical data supports sustained benefits with dose adjustments, minimizing hospitalizations for respiratory failure.​\n\nImproved Survival Metrics: In combination therapies for NSCLC, it extends progression-free survival, offering valuable time for patients.​\n\nThese advantages make Nintedanib 100 mg a cornerstone in modern pulmonology and oncology, backed by phase III trials demonstrating statistically significant outcomes in diverse patient populations.​\n\nSide Effects of Nintedanib 100 mg\nWhile effective, Nintedanib 100 mg can cause gastrointestinal side effects as the most common issue, affecting over 60% of users primarily due to its impact on kinase signaling in the gut. Diarrhea often starts within the first two weeks and is typically manageable with dose reduction or antidiarrheal agents like loperamide. Other frequent effects include nausea, vomiting, and decreased appetite, which may lead to weight loss if not addressed.​\n\nMore serious side effects warrant close monitoring:\n\nLiver Enzyme Elevations: Hepatotoxicity occurs in about 10-15% of patients, necessitating monthly liver function tests, especially in those with pre-existing liver conditions.​\n\nCardiovascular Risks: Potential for arterial thromboembolism or hypertension; baseline cardiac evaluation is recommended.​\n\nBleeding Events: Due to VEGF inhibition, minor bleeding like epistaxis is common, but gastrointestinal hemorrhage requires immediate attention.​\n\nRare but Severe: Interstitial lung disease progression (paradoxical worsening), perforations, or severe infections in immunocompromised patients.​\n\nPatients should report persistent diarrhea, abdominal pain, jaundice, or unusual fatigue promptly. Contraindications include pregnancy (category D), active bleeding, or hypersensitivity, with strong recommendations against use in moderate to severe hepatic impairment.​\n\nDosage and Administration Insights\nTypically initiated at 150 mg twice daily for IPF and ILD, Nintedanib 100 mg allows for flexible dosing—starting lower at 100 mg BID if tolerated poorly, with food to reduce GI upset. For NSCLC, it's 200 mg BID with docetaxel cycles. Regular monitoring every 2-3 months adjusts for tolerance, emphasizing adherence to slow disease modification.​\n\nConclusion\nNintedanib 100 mg represents a breakthrough in managing progressive fibrotic lung diseases and select cancers, delivering targeted inhibition of fibrotic and angiogenic pathways for tangible clinical benefits. Its ability to slow FVC decline, enhance patient quality of life, and integrate into combination regimens underscores its value, despite manageable side effects like diarrhea that respond well to supportive care. For those battling IPF, SSc-ILD, or NSCLC, Nintedanib 100 mg offers a proactive defense against relentless progression, empowering longer, more active lives under specialist guidance.​", "price": 795.0, "discountamount": 296.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "one capsule", "weight loss", "scar tissue", "key players", "Key Benefits", "lung function", "initial stages", "abdominal pain", "fibrous tissue", "key ingredient", "Bleeding Events", "fibrotic tissue", "daily activities", "tyrosine kinases", "fibrotic process", "Nintedanib 100 mg", "multiple pathways", "active ingredient", "sudden worsenings", "crucial medication", "recommended dosage", "Decreased Appetite", "signaling pathways", "multiple receptors", "overall well-being", "disease progression", "acute exacerbations", "healthcare provider", "Common side effects", "elevated liver enzymes", "Gastrointestinal Issues", "other fibrotic diseases", "Liver Enzyme Elevations", "tyrosine kinase inhibitor", "progressive lung conditions", "other fibrotic lung diseases", "idiopathic pulmonary fibrosis", "potent pharmaceutical formulation", "fibroblast growth factor receptor", "platelet-derived growth factor receptor", "vascular endothelial growth factor receptor" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1971, "imageuri": "https://productimages.withfloats.com/actual/66d999d4f2036c2969cdeca8.png", "tileimageuri": "https://productimages.withfloats.com/tile/66d999d4f2036c2969cdeca8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-05T11:45:16.665Z", "updatedon": "2026-03-14T06:46:45.85Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//nintedanib-100-mg/1971", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NINTEDONE 100 ", "category": "NEPHROLOGYRANGE", "tags": [ "lung conditions and certain cancers", "Nintedanib 100 mg", "pulmonary fibrosis (IPF)", "fibrosis and lung cancer", "nintedanib 100 mg", "nintedanib capsules 100 mg", "nintedanib 100 mg capsules", "nintedanib 100 mg medicine", "nintedanib 100 mg tablet uses", "what is nintedanib 100 mg used for", "how nintedanib 100 mg works", "nintedanib 100 mg uses and benefits", "nintedanib 100 mg for lung disease", "nintedanib 100 mg for pulmonary fibrosis", "nintedanib 100 mg for idiopathic pulmonary fibrosis", "nintedanib 100 mg for interstitial lung disease", "nintedanib capsules for chronic lung disease", "nintedanib 100 mg price in india", "nintedanib 100 mg capsules price", "buy nintedanib 100 mg online", "nintedanib 100 mg supplier india", "nintedanib 100 mg manufacturer", "when should nintedanib 100 mg be taken", "who should take nintedanib 100 mg", "can nintedanib slow lung fibrosis", "how long to take nintedanib 100 mg", "does nintedanib cure pulmonary fibrosis" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6661a73687f0960e14a2c739", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "mycophenolate sodium 360 mg", "description": "MYCOPLASM S 360 \nMycophenolate sodium 360 mg is an essential immunosuppressant medication designed to prevent organ transplant rejection, particularly for kidney, heart, and liver transplants. As the sodium salt of mycophenolic acid, it delivers 360 mg of the active moiety per tablet, providing targeted immune suppression to help patients maintain their new organs long-term. This product stands out for its enteric-coated formulation, which enhances gastrointestinal tolerability compared to other forms, making it a preferred choice in post-transplant care regimens.​\n\nUses of Mycophenolate Sodium 360 mg\nMycophenolate sodium 360 mg primarily serves as a prophylactic agent against acute rejection in adult and pediatric patients receiving allogeneic renal, cardiac, or hepatic transplants. It works alongside other immunosuppressants like cyclosporine and corticosteroids to create a balanced regimen that minimizes the risk of graft loss. Clinically, it proves effective in de novo transplant recipients, where starting therapy early post-surgery significantly reduces rejection episodes. Beyond transplants, off-label applications include managing refractory autoimmune conditions such as lupus nephritis or myasthenia gravis, where immune overactivity damages tissues.​\n\nThe drug targets the proliferation of T- and B-lymphocytes, key players in immune responses that can attack transplanted organs. In renal transplant patients, for instance, it helps preserve kidney function by curbing antibody-mediated rejection. Its role extends to maintenance therapy, where consistent dosing sustains immunosuppression without excessive toxicity. Healthcare providers often adjust it based on patient response and trough levels of the active metabolite, mycophenolic acid (MPA), ensuring optimal therapeutic outcomes.​\n\nKey Benefits of Mycophenolate Sodium 360 mg\nMycophenolate sodium 360 mg offers several advantages that make it a cornerstone in transplant medicine. One primary benefit is its selective inhibition of lymphocyte proliferation, sparing other cell types and reducing broad-spectrum immunosuppression risks. This leads to fewer opportunistic infections compared to older agents like azathioprine. The enteric coating minimizes upper GI upset, improving patient compliance—studies show higher adherence rates with this formulation.​\n\nEnhanced Graft Survival: Prolongs organ viability by effectively suppressing cell-mediated and humoral immunity, with clinical data showing reduced biopsy-proven rejection rates.\n\nImproved Tolerability: Lower incidence of nausea and diarrhea due to delayed-release technology, allowing twice-daily dosing without food restrictions.\n\nFlexible Dosing: Equivalent to 720 mg mycophenolate mofetil, but with predictable MPA exposure via enterohepatic recirculation for steady-state efficacy.\n\nPediatric Suitability: Approved for children over 2 years in renal transplants, supporting growth without compromising safety.\n\nCost-Effective Long-Term Option: Balances efficacy and side effect profile, potentially lowering overall healthcare costs from fewer rejections or hospitalizations.​\n\nPatients experience better quality of life, with sustained energy levels and fewer interruptions from acute rejection crises. Its metabolism to MPA via liver glucuronidation ensures reliable pharmacokinetics, even in patients with mild renal impairment.​\n\nSide Effects of Mycophenolate Sodium 360 mg\nWhile highly effective, mycophenolate sodium 360 mg carries risks typical of immunosuppressants, necessitating vigilant monitoring. Common adverse effects stem from its impact on rapidly dividing cells, particularly in the gut and bone marrow.\n\nCommon Side Effects\nGastrointestinal issues like diarrhea, nausea, vomiting, and abdominal pain, affecting up to 30-50% of users.\n\nHeadache, insomnia, and tremor, often mild and transient.\n\nInfections such as urinary tract or respiratory, due to moderated immunity.\n\nHypertension or peripheral edema, manageable with supportive care.\n\nLeukopenia or anemia, requiring periodic blood counts.​\n\nSerious Side Effects\nSevere myelosuppression leading to neutropenia or thrombocytopenia, which can increase infection or bleeding risks.\n\nProgressive multifocal leukoencephalopathy (PML), a rare brain infection linked to JC virus reactivation.\n\nGastrointestinal perforation or bleeding, especially in at-risk patients.\n\nIncreased malignancy risk, including lymphoma or skin cancers, over long-term use.\n\nHypersensitivity reactions like rash or anaphylaxis.​\n\nRegular complete blood counts, viral monitoring (e.g., CMV, BK virus), and skin exams mitigate these risks. Dose reductions or discontinuation may be needed if counts drop significantly.​\n\nMechanism of Action\nMycophenolate sodium 360 mg rapidly hydrolyzes to mycophenolic acid (MPA), a potent, reversible, non-competitive inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH). This enzyme catalyzes the rate-limiting step in de novo guanine nucleotide synthesis, depleting guanosine nucleotides essential for T- and B-cell DNA replication. Lymphocytes, reliant on this pathway, undergo proliferation arrest, suppressing both cell-mediated immunity and antibody production.​\n\nMPA also hinders glycosylation of adhesion molecules on lymphocytes and monocytes, impeding their migration to graft sites. It reduces nitric oxide production in macrophages without affecting endothelial cells, curbing inflammation. Enterohepatic recirculation of the glucuronide metabolite (MPAG) prolongs MPA exposure, enhancing efficacy. Protein binding to albumin (around 97%) ensures targeted delivery, with clearance primarily renal for the inactive form.​\n\nDosage and Administration Guidelines\nStandard dosing for renal transplant is 720 mg (two 360 mg tablets) twice daily, starting within 72 hours post-surgery. Adjustments occur for hepatic or cardiac transplants, often alongside cyclosporine. Therapeutic drug monitoring of MPA AUC (area under curve) optimizes levels between 30-60 mcg·h/mL. Take on an empty stomach for best absorption, though food has minimal impact due to the coating.​\n\nPrecautions and Warnings\nAvoid in pregnancy (Category D) due to teratogenicity—use contraception and regular pregnancy tests. Contraindicated in active untreated infections. Monitor for GI bleeding in ulcerative colitis patients. Drug interactions with antacids, cholestyramine, or rifampin alter MPA levels. Live vaccines are prohibited.​\n\nConclusion\nMycophenolate sodium 360 mg represents a vital advancement in transplant immunosuppression, offering robust protection against rejection with a favorable benefit-risk profile. Its targeted action on lymphocytes, combined with improved GI tolerance, empowers patients to thrive post-transplant. By integrating it into comprehensive regimens with close monitoring, healthcare teams maximize graft success and patient well-being. Always consult a specialist for personalized guidance to harness its full potential safely.\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nORDER Now: \nhttps://www.sterisonline.com/product/mycoplasm-s-360-133670\n\n\n\n\n\n\n", "price": 767.0, "discountamount": 567.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "dose", "risk", "body", "part", "ORDER", "360mg", "Email", "cells", "dosage", "nausea", "vomiting", "schedule", "headache", "strength", "WhatsApp", "diarrhea", "activity", "rejection", "treatment", "infections", "supplements", "information", "MYCOPLASM S", "sterispharma", "sterisonline", "stomach pain", "blood counts", "immune system", "complications", "liver problems", "liver function", "other medications", "Regular monitoring", "medical conditions", "healthcare provider", "Common side effects", "Serious side effects", "white blood cell count", "potential drug interactions", "optimal therapeutic effects", "combination therapy regimen", "organ transplant recipients", "Mycophenolate Sodium therapy", "other immunosuppressive drugs" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1474, "imageuri": "https://productimages.withfloats.com/actual/6661a739c749b7962dbc08c6.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/6661a739c749b7962dbc08c6.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:10:30.488Z", "updatedon": "2026-03-12T08:02:36.733Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//mycophenolate-sodium-360-mg/1474", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "MYCOPLASM S 360 ", "category": "Oncology", "tags": [ "MYCOPLASM S 360", "Mycophenolate sodium (360mg)", "Mycophenolate sodium 360 mg price", "Mycophenolate sodium 360 mg brands", "Mycophenolate sodium 360 mg side effects", "Myfortic 360 alternative", "Myfortic 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6a86e496cc4491de1ed77dfd", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Etoricoxib & Cyclobenzaprine Hydrochloride Tablets", "description": "ERITOCOX BENZ 90/5 is a fixed-dose combination tablet pairing Etoricoxib 90 mg, a selective COX-2 anti-inflammatory, with Cyclobenzaprine Hydrochloride 5 mg, a centrally acting muscle relaxant. It is prescribed for short-term relief of acute musculoskeletal problems where pain, swelling, and muscle tightness occur together — think a sudden low-back strain, a stiff neck, or a flare-up of arthritis where the surrounding muscles clamp down defensively. Rather than treating the inflammation alone or the spasm alone, this tablet addresses both mechanisms in one dose, which can mean fewer pills and a more complete response for short, acute episodes. It is a prescription-only (Schedule H) medicine, produced under WHO-GMP and ISO-certified manufacturing standards by Steris Healthcare Pvt. Ltd. Typical side effects include drowsiness, dry mouth, and mild stomach upset; because the combination carries cardiovascular, gastrointestinal, and kidney considerations, it should only be used under a doctor's supervision. This page walks through what the tablet does, how it works, correct usage, safety information, and answers to the questions people most often ask.\n\nWhat Is ERITOCOX BENZ 90/5?\n\nPain from an acute back injury, a wrenched neck, or an arthritis episode almost never travels alone — it tends to bring a tense, guarded muscle along with it that makes every movement feel worse. ERITOCOX BENZ 90/5 was formulated with that pattern in mind, folding two separate mechanisms into a single tablet rather than requiring two prescriptions.\n\nActive Ingredient\tStrength\tRole\nEtoricoxib\t90 mg\tSelective COX-2 inhibitor for inflammatory pain\nCyclobenzaprine Hydrochloride\t5 mg\tCentrally acting skeletal muscle relaxant\n\nEach tablet is manufactured by Steris Healthcare Pvt. Ltd., a WHO-GMP and ISO-certified pharmaceutical company, so every batch meets verified potency and quality benchmarks.\n\nWhy This Combination Makes Sense\n\nMusculoskeletal pain is rarely a single-track problem. When tissue is injured or irritated, inflammation flares up locally — and nearby muscles frequently respond by tightening protectively. That protective tightening, the spasm, often becomes a pain generator of its own. Treat only the inflammation and the spasm can linger; treat only the spasm and the underlying inflammation keeps driving discomfort.\n\nERITOCOX BENZ 90/5 is built to intervene on both fronts at once:\n\nEtoricoxib addresses the chemical cascade responsible for pain and swelling at the injured site.\nCyclobenzaprine works through the central nervous system to calm the muscle guarding that so often rides alongside that pain.\nMechanism of Action: How ERITOCOX BENZ 90/5 Works\n\nEtoricoxib selectively inhibits the COX-2 enzyme — the enzyme the body ramps up at sites of tissue damage or irritation to manufacture prostaglandins, the chemical messengers behind pain, swelling, and localized heat. Because it targets COX-2 specifically rather than blocking both COX-1 and COX-2 the way older, non-selective NSAIDs do, etoricoxib is designed to control inflammatory pain while leaving more of the COX-1 activity that protects the stomach lining relatively undisturbed.\n\nCyclobenzaprine Hydrochloride takes a different route entirely — its primary site of action is the brainstem, not the muscle fiber itself. By dampening excessive motor signaling sent to skeletal muscle, it reduces spasm and stiffness without producing the broad muscle weakness that a directly-acting muscle agent might cause.\n\nPut together, the tablet delivers a two-pronged effect: peripheral anti-inflammatory action from etoricoxib, layered with central muscle relaxation from cyclobenzaprine.\n\n[Reviewer placeholder: insert verified pharmacokinetic data (onset, half-life, bioavailability) once confirmed by medical/regulatory team — do not publish unverified figures.]\n\nClinical Uses of ERITOCOX BENZ 90/5\n\nA physician may prescribe this combination for short-term management of acute conditions where pain, inflammation, and spasm show up together, including:\n\nCondition\tTypical Presentation\nAcute lower back pain\tPain with associated muscle guarding/spasm\nNeck strain / cervical spasm\tStiff, restricted neck movement\nSprains, strains, overuse injuries\tMusculoskeletal trauma with inflammatory pain\nOsteoarthritis flare-ups\tJoint pain accompanied by surrounding muscle tightness\nPostural or occupational muscle pain\tWork- or posture-related inflammation and tension\nMovement restriction linked to spasm\tReduced range of motion driven by muscular guarding\n\nSuitability for any of the above must be confirmed by a doctor based on your specific diagnosis and medical history.\n\nKey Benefits of ERITOCOX BENZ 90/5\nOne tablet, two mechanisms — anti-inflammatory pain relief and muscle-spasm relief combined, simplifying an otherwise two-drug regimen.\nSite-focused inflammation control — etoricoxib's COX-2 selectivity is intended to concentrate its effect where inflammation is actually active.\nA comparatively gentler GI footprint — COX-2-selective action is generally linked to lower gastrointestinal irritation risk than older non-selective NSAIDs, though vigilance is still warranted.\nLoosens spasm-related stiffness — cyclobenzaprine's central action helps release tight, guarded muscles restricting movement.\nAids functional recovery — easing both pain and spasm can make it more realistic to resume light activity, stretching, or physiotherapy once your doctor clears you.\nStreamlined short-course dosing — a once-daily schedule (as prescribed) cuts down pill burden versus taking an NSAID and a muscle relaxant separately.\nDosage & Administration\n\nThe following is general reference information — your doctor's specific prescription always takes precedence.\n\nTake ERITOCOX BENZ 90/5 exactly as prescribed, generally once a day, with or without food.\nSwallow the tablet whole with water; avoid crushing or chewing unless your doctor tells you otherwise.\nTreatment is typically short — anywhere from a few days to roughly two weeks — reflecting the acute, self-limiting nature of most pain-and-spasm episodes.\nIf a dose is missed, take it as soon as you remember, but skip it entirely if the next dose is nearly due. Never double up to make up for a missed dose.\nDo not extend the treatment period or adjust your dose independently, even if symptoms haven't fully resolved.\nSide Effects of ERITOCOX BENZ 90/5\nCommon Side Effects\nDrowsiness or sleepiness\nDizziness\nDry mouth\nHeadache\nStomach discomfort or indigestion\nNausea\nFatigue\nMild elevation in blood pressure in some individuals\nSerious Side Effects — Seek Medical Help Promptly\nSigns of gastrointestinal bleeding, such as black stools or vomiting blood\nA severe allergic reaction — swelling of the face or throat, breathing difficulty, or widespread rash\nChest pain, irregular heartbeat, or other symptoms suggestive of a cardiovascular event\nYellowing of the skin or eyes, which may point to liver involvement\nA noticeable drop in urine output, which may suggest kidney impairment\nSevere dizziness, confusion, or fainting\n\nIf any of these serious symptoms appear, stop the medicine and get medical attention immediately.\n\nPrecautions & Warnings\nShare your full medical history with your doctor before starting, including any heart, kidney, or liver conditions.\nUse cautiously — or avoid altogether — if you have a history of stomach ulcers or gastrointestinal bleeding.\nGenerally not advised for people with uncontrolled high blood pressure, existing heart disease, or a prior stroke, unless a doctor specifically clears its use.\nSteer clear of alcohol, since it can amplify cyclobenzaprine's sedative effect and add to gastrointestinal risk.\nCyclobenzaprine may cause drowsiness or dizziness — hold off on driving or operating machinery until you know how the tablet affects you.\nDon't combine ERITOCOX BENZ 90/5 with other NSAIDs, painkillers, or sedating medicines without checking with your doctor first.\nAvoid the medicine if you have known hypersensitivity to etoricoxib, cyclobenzaprine, or related compounds.\nNot generally recommended during pregnancy or breastfeeding unless a doctor specifically advises otherwise.\nAvoid combining with MAO inhibitors, or using shortly after stopping them.\nDrug Interactions to Flag With Your Doctor\n\nDisclose every prescription medicine, over-the-counter product, and supplement you take. Extra caution is needed around medicines affecting:\n\nBlood pressure regulation\nKidney function\nBlood clotting\nCentral nervous system activity (sedatives, other muscle relaxants)\nLiver metabolism\nOther anti-inflammatory or pain-relief medicines\nConclusion\n\nERITOCOX BENZ 90/5 brings Etoricoxib 90 mg and Cyclobenzaprine Hydrochloride 5 mg together to tackle a problem that rarely presents as a single issue — pain, inflammation, and muscle spasm that reinforce one another in acute musculoskeletal conditions. By acting on both the inflammatory and muscular sides of that cycle, it offers a more rounded short-term response than either ingredient could provide alone.\n\nGiven the genuine cardiovascular, gastrointestinal, kidney, and central-nervous-system considerations involved, ERITOCOX BENZ 90/5 is meant strictly for short, doctor-supervised courses — not casual or extended self-treatment. Always check with your doctor to confirm whether this combination is right for your condition, medical history, and current medications.\n\nPrescription only – consult your doctor.\n\nFrequently Asked Questions (Google & AI Mode / Voice Search Optimized)\n\n1. What is ERITOCOX BENZ 90/5 used for? It's typically prescribed for short-term relief of acute musculoskeletal issues — such as back pain, neck strain, or an arthritis flare-up — where pain, inflammation, and muscle spasm show up together.\n\n2. Is ERITOCOX BENZ 90/5 a muscle relaxant? It's a combination tablet: the muscle-relaxing effect comes from its Cyclobenzaprine Hydrochloride component, while Etoricoxib supplies the pain-relieving, anti-inflammatory action.\n\n3. Is Etoricoxib a strong painkiller? Etoricoxib is an effective selective COX-2 inhibitor typically used for moderate inflammation-related pain, such as arthritis or an acute musculoskeletal injury. Its appropriateness for your level of pain should be assessed by a doctor.\n\n4. Is Etoricoxib safe for the kidneys? As with other NSAIDs, etoricoxib can influence kidney function, particularly with extended use, higher doses, dehydration, or existing kidney disease. It should be used carefully and only under medical guidance if kidney health is a concern.\n\n5. Should ERITOCOX BENZ 90/5 be taken in the morning or at night? It's usually taken once a day at a time your doctor sets. Since cyclobenzaprine can cause drowsiness, many doctors lean toward an evening dose — but always stick to your specific prescription.\n\n6. What are the common side effects of ERITOCOX BENZ 90/5? Frequently reported effects include drowsiness, dizziness, dry mouth, headache, stomach discomfort, and mild fatigue. Most fade on their own, but persistent symptoms should be reported to your doctor.\n\n7. How fast does ERITOCOX BENZ 90/5 start working? Etoricoxib tends to absorb fairly quickly, and many people feel pain relief within roughly an hour, though onset can vary by individual and whether the tablet is taken with food.\n\n8. What should be avoided while on ERITOCOX BENZ 90/5? Skip alcohol, avoid taking other NSAIDs or painkillers without medical advice, and hold off on driving or operating machinery if you're feeling drowsy or dizzy.\n\n9. How many days can ERITOCOX BENZ 90/5 be taken? It's usually prescribed for a short stretch — a few days up to around two weeks — matching how acute conditions typically resolve. Anything longer needs your doctor's review.\n\n10. What are the benefits of ERITOCOX BENZ 90/5? It delivers combined relief from pain, inflammation, and muscle spasm in one tablet, which can make it easier to move normally and get back to daily activity sooner when used as directed.\n\n11. How safe is ERITOCOX BENZ 90/5? Taken exactly as prescribed and for the recommended duration, it's generally considered safe for most adults. It does carry cardiovascular, gastrointestinal, kidney, and liver-related risks that call for medical supervision, especially if you already have related conditions.\n\n12. Can ERITOCOX BENZ 90/5 be used for knee pain? Yes — its etoricoxib component is commonly used for joint pain tied to osteoarthritis or an acute injury, including the knee, by reducing the underlying inflammation. A doctor should confirm suitability first.\n\n13. Does ERITOCOX BENZ 90/5 cause drowsiness? Yes — drowsiness and dizziness are known effects linked to its cyclobenzaprine component. Avoid driving or tasks requiring full alertness until you know how it affects you.\n\n14. Can ERITOCOX BENZ 90/5 be bought without a prescription? No. This is a prescription-only medicine meant to be taken solely under a qualified doctor's supervision — it isn't meant for self-prescribing or extended use without medical oversight.\n\n15. Can ERITOCOX BENZ 90/5 be taken with food? It can generally be taken with or without food, though taking it with food may ease stomach discomfort for some people. Follow your doctor's specific instructions.\n\n16. Is ERITOCOX BENZ 90/5 habit-forming? Cyclobenzaprine isn't considered addictive with typical short-term use, but the tablet should still be taken only for the prescribed duration and not restarted on your own without medical advice.\n\n17. Who should avoid taking ERITOCOX BENZ 90/5? People with active stomach ulcers, significant heart, kidney, or liver disease, known hypersensitivity to NSAIDs, or those who are pregnant or breastfeeding should avoid it unless a doctor specifically clears its use.", "price": 222.0, "discountamount": 67.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2495, "imageuri": "https://productimages.withfloats.com/actual/6a86e4990f089c4695c57658.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a86e4990f089c4695c57658.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-08-20T11:27:18.403Z", "updatedon": "2026-08-20T11:27:18.403Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//etoricoxib-cyclobenzaprine-hydrochloride-tablets/2495", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ERITOCOX BENZ 90/5", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }